P95 BV, a Belgium-based global provider of epidemiology and clinical research solutions with a focus on vaccines and infectious diseases, announced on Tuesday a majority recapitalisation by Ampersand Capital Partners, a US-based private equity company specialising in growth equity investments in the life science and healthcare sectors.

The investment is to support the growth of P95's core business and fund the expansion of its CRO services supporting the vaccine and infectious disease end-markets. As part of the deal, P95 has named Benoit Bouche as chairman of the company's board of directors.

Thomas Verstraeten, P95 CEO and founder, said, 'P95 is excited to have the support of Ampersand as we pursue our vision to be the world's favourite global research partner in support of vaccine and infectious disease therapeutic development and use. We believe Ampersand's resources and expertise will enable our team to accelerate growth while expanding the scope and depth of clinical support services we provide to vaccine stakeholders across the globe. This will help fulfil our purpose to bring better health for everybody, everywhere.'